Cumulative cefepime exposure in cancer patients is associated with an increased risk of ertapenem non-susceptible, meropenem susceptible Enterobacterales bacteremia
Preprint
Abstract
Carbapenem resistance in non-carbapenemase producing Enterobacterales can display susceptibility discordance (e.g., ertapenem-non-susceptible, meropenem-susceptible), often in patients with prior antimicrobial use. We aim to characterize risk factors for carbapenem susceptibility discordant Enterobacterales (CSD-E) bloodstream infections in immunocompromised patients. We performed a retrospective, single-center study comparing adults with Enterobacterales BSI who developed subsequent carbapenem susceptibility concordant (CSC;meropenem and ertapenem susceptible) or CSD-E BSI with the same organism within one year. Patients who developed subsequent CSD-E BSI were matched to those with repeat CSC-E BSI. Logistic regression models evaluated CSD-E risk factors. Time-varying covariate Cox proportional hazards models evaluated time-dependent changes in antibiotic exposure when estimating the association between antibiotic use and CSD-E. Comparative genomics of available paired whole-genome sequencing (WGS) data was performed to assess genetic relatedness and antimicrobial resistance (AMR) gene content. Beta-lactam survival mechanisms (BLSM) were assessed via Tolerance Disk Test (TDTest) and Population Analysis Profiling (PAP). We evaluated 829 patients with Enterobacterales BSI. Repeat BSI was CSC-E in 81 patients (9.8%) and CSD-E in 14 patients (1.7%). Matching provided 43 CSC-E controls and 14 CSD-E cases. Univariate analysis revealed any ceftazidime-avibactam (CZA) exposure was associated with developing CSD-E BSI (odds ratio[OR],7.41;p=0.01). Time-varying covariate Cox regression identified each additional day of cefepime is associated with CSD-E BSI development (hazard ratio[HR],1.055;p=0.016). Genomic data revealed beta-lactamase amplification and outer membrane porin mutations as potential CSD-E development mechanisms. CSD-E BSI risk factors in immunocompromised patients may include any CZA exposure and cumulative cefepime exposure. Further studies are warranted to validate CSD-E risk factors.Keywords
This publication has 26 references indexed in Scilit:
- One day in Denmark: whole-genome sequence-based analysis of Escherichia coli isolates from clinical settingsJournal of Antimicrobial Chemotherapy, 2025
- Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant EnterobacteralesJournal of Antimicrobial Chemotherapy, 2024
- Review on the effect of chemotherapy on the intestinal barrier: Epithelial permeability, mucus and bacterial translocationBiomedicine & Pharmacotherapy, 2023
- Distinctive Features of Ertapenem-Mono-Resistant Carbapenem-Resistant Enterobacterales in the United States: A Cohort StudyOpen Forum Infectious Diseases, 2021
- Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort studyThe Lancet Infectious Diseases, 2020
- Effect of varying federal definitions on prevalence and characteristics associated with carbapenem-resistant Enterobacteriaceae in veterans with spinal cord injuryAmerican Journal of Infection Control, 2018
- TDtest: easy detection of bacterial tolerance and persistence in clinical isolates by a modified disk-diffusion assayScientific Reports, 2017
- Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae BacteremiaClinical Infectious Diseases, 2016
- Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort studyClinical Microbiology and Infection, 2015
- Ertapenem-Resistant Enterobacteriaceae Risk Factors for Acquisition and OutcomesInfection Control & Hospital Epidemiology, 2010